67-LB: Time Spent in Glycaemic Ranges and Carbohydrate Intake during Cycling in Professional Cyclists with Type 1 Diabetes
| العنوان: | 67-LB: Time Spent in Glycaemic Ranges and Carbohydrate Intake during Cycling in Professional Cyclists with Type 1 Diabetes |
|---|---|
| المؤلفون: | Peter Hendrik Lagrou, Phil Southerland, Kristina Skroce, Christoph Stettler, Richard M. Bracken, Miles Fisher, Othmar Moser, Charlotte A. Hayes, Michael C. Riddell, Bruce W. Bode, Olivia McCarthy, Federico Y. Fontana, Sam N. Scott, Luca Festa, Mark P. Christiansen, Max L. Eckstein |
| المصدر: | Diabetes. 68 |
| بيانات النشر: | American Diabetes Association, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Type 1 diabetes, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Hypoglycemia, medicine.disease, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, Internal Medicine, Interstitial glucose, Medicine, business, Cycling, Training period, Glycemic, Carbohydrate intake |
| الوصف: | Aim: This observational study examined in-ride interstitial glucose data and nutritional intake in a UCI-accredited professional cycling team with type 1 diabetes (T1D) over a nine-day training camp. Methods: Sixteen male professional road cyclists with T1D (age 27±4 years, T1D duration 11±5 years, BMI 21.6±1.5 kg·min-2, HbA1c 6.8±0.6 %, O2max 71.3±3.9 ml·kg·min-1) on multiple daily injections performed eight rides over nine days lasting between 2 and 6 h, traversing 56 to 182 km/day. Cycle glycemic information (G6, Dexcom) was collected, stratified into glycemic time in ranges; hypoglycemia (Level 1: 54-70, Level 2: 299 mg/dL) and analyzed for time spent (%) within each range. Nutritional intake during each ride was determined and reported as median (range). Results: Average percentage time spent in euglycemia during cycling was 78±6% (daily range 70-86%). Hypoglycemia during cycling was 3±4% (range 0-11%, Level 1), and 1±2% (range 0-2%, Level 2). No hypoglycemic event required assistance. Percentage time spent in hyperglycemia during cycling was 17±7% (range 8-27%, Level 1), and 1±2 % (range 0-5%, Level 2). The contribution of carbohydrates, fat and protein to total in-ride energy intake was 83.8±15.4, 12.6±8.1 and 1.2±0.6 %, respectively. Macronutrient intake was dependent on cycle duration with greater carbohydrate intake rate on longer rides (2-hour cycle: 20 (4-82) g/h vs. 6-hour cycle: 51 (17-86) g/h). Conclusions: Professional cyclists with T1D maintained a large proportion of time in a euglycemic range during intense cycling sessions over a nine-day training period. The low occurrence of in-ride hypoglycemia, mostly at Level 1, suggests a protective role for consumption of carbohydrate-rich foods to maintain glycaemia, especially during longer rides. However, time spent in Level 1 hyperglycemia during cycling was notable and should be monitored. Disclosure O. McCarthy: None. O. Moser: Research Support; Self; Abbott, Dexcom, Inc., Novo Nordisk A/S. M.L. Eckstein: Research Support; Self; Novo Nordisk A/S. S.N. Scott: None. M. Riddell: Advisory Panel; Self; Xeris Pharmaceuticals, Inc. Consultant; Self; Lilly Diabetes. Research Support; Self; Dexcom, Inc., Insulet Corporation, Novo Nordisk Inc., Sanofi. Speaker’s Bureau; Self; Medtronic MiniMed, Inc., OmniPod. Stock/Shareholder; Self; Zucara Therapeutics Inc. M. Fisher: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Mylan, NAPP Pharmaceuticals Limited, Novo Nordisk A/S. Speaker’s Bureau; Self; Eli Lilly and Company, Sanofi. F.Y. Fontana: None. K. Skroce: None. L. Festa: None. P.H. Lagrou: None. P. Southerland: Other Relationship; Self; Novo Nordisk Inc. C.A. Hayes: Other Relationship; Self; Novo Nordisk A/S. M.P. Christiansen: Research Support; Self; Abbott, Biolinq, Dexcom, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medtronic MiniMed, Inc., Novo Nordisk A/S, Sanofi-Aventis, Xeris Pharmaceuticals, Inc. B.W. Bode: Consultant; Self; ADOCIA, Lexicon Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; Becton, Dickinson and Company, Dexcom, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Eyenuk Inc., Insulet Corporation, National Institutes of Health, Novo Nordisk Inc., Sanofi Research & Development, Senseonics, Xeris Pharmaceuticals, Inc. Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi US, Senseonics. Stock/Shareholder; Self; AgaMatrix, Glytec, LLC. C. Stettler: None. R.M. Bracken: None. |
| تدمد: | 1939-327X 0012-1797 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::8bd8587efce05f9d3ea5f5d1fb057062Test https://doi.org/10.2337/db19-67-lbTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi...........8bd8587efce05f9d3ea5f5d1fb057062 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1939327X 00121797 |
|---|